FR06C0009I2 - - Google Patents

Info

Publication number
FR06C0009I2
FR06C0009I2 FR06C0009C FR06C0009C FR06C0009I2 FR 06C0009 I2 FR06C0009 I2 FR 06C0009I2 FR 06C0009 C FR06C0009 C FR 06C0009C FR 06C0009 C FR06C0009 C FR 06C0009C FR 06C0009 I2 FR06C0009 I2 FR 06C0009I2
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR06C0009C
Other languages
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22622452&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR06C0009(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of FR06C0009I1 publication Critical patent/FR06C0009I1/fr
Application granted granted Critical
Publication of FR06C0009I2 publication Critical patent/FR06C0009I2/fr
Active legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Dental Preparations (AREA)
  • Lubricants (AREA)
  • Thermal Transfer Or Thermal Recording In General (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FR06C0009C 1993-12-21 2006-03-13 Active FR06C0009I2 (enExample)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17108393A 1993-12-21 1993-12-21
PCT/US1994/014236 WO1995017407A1 (en) 1993-12-21 1994-12-20 Tetrahydrofuran antifungals

Publications (2)

Publication Number Publication Date
FR06C0009I1 FR06C0009I1 (enExample) 2006-05-19
FR06C0009I2 true FR06C0009I2 (enExample) 2006-12-29

Family

ID=22622452

Family Applications (1)

Application Number Title Priority Date Filing Date
FR06C0009C Active FR06C0009I2 (enExample) 1993-12-21 2006-03-13

Country Status (28)

Country Link
EP (1) EP0736030B1 (enExample)
JP (1) JP2834889B2 (enExample)
KR (1) KR0179990B1 (enExample)
CN (1) CN1064685C (enExample)
AT (1) ATE204875T1 (enExample)
AU (1) AU681753B2 (enExample)
BR (1) BR1100154B1 (enExample)
CA (1) CA2179396C (enExample)
CO (1) CO4520281A1 (enExample)
CZ (1) CZ294823B6 (enExample)
DE (2) DE122006000004I2 (enExample)
DK (1) DK0736030T3 (enExample)
ES (1) ES2159623T3 (enExample)
FI (1) FI118470B (enExample)
FR (1) FR06C0009I2 (enExample)
HU (1) HU225062B1 (enExample)
IL (1) IL112081A (enExample)
LU (1) LU91216I2 (enExample)
MY (1) MY130217A (enExample)
NL (1) NL300219I2 (enExample)
NO (2) NO316173B1 (enExample)
NZ (1) NZ278713A (enExample)
PL (1) PL181193B1 (enExample)
PT (1) PT736030E (enExample)
SK (1) SK283035B6 (enExample)
TW (1) TW377349B (enExample)
WO (1) WO1995017407A1 (enExample)
ZA (1) ZA9410142B (enExample)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG48386A1 (en) * 1994-01-24 1998-04-17 Janssen Pharmaceutica Nv Watersoluble azole antifungals
ATE240319T1 (de) * 1995-06-02 2003-05-15 Schering Corp Antifungale tetrahydrofurane
JPH11507668A (ja) * 1995-06-19 1999-07-06 シェーリング コーポレイション テトラヒドロフラン抗真菌剤
US5698557A (en) * 1995-06-19 1997-12-16 Schering Corporation Hydroxy-substituted antifungals
NZ324616A (en) * 1995-12-20 1999-05-28 Schering Corp Process for preparation of hydrazides using hydrazones and grignard reagents
US5834472A (en) * 1996-05-24 1998-11-10 Schering Corporation Antifungal composition with enhanced bioavailability
RU2207119C2 (ru) * 1996-05-24 2003-06-27 Шеринг Корпорейшн Противогрибковый состав с повышенной биодоступностью
US5846971A (en) * 1996-06-28 1998-12-08 Schering Corporation Oral antifungal composition
JP2000514057A (ja) * 1996-06-28 2000-10-24 シェーリング コーポレイション 増強されたバイオアベイラビリティを有する抗真菌剤の固溶体
US5972381A (en) * 1996-06-28 1999-10-26 Schering Corporation Solid solution of an antifungal agent with enhanced bioavailability
EP0914100A1 (en) * 1996-06-28 1999-05-12 Schering Corporation Oral composition comprising a triazole antifungal compound
EP0942907A1 (en) * 1996-11-12 1999-09-22 Sepracor, Inc. 2r, 4s, s, r- and 2s, 4r, s, r-hydroxyitraconazole
CN1237173A (zh) * 1996-11-12 1999-12-01 塞普拉科公司 2r,4s,r,r-和2s,4r,r,r-羟基伊曲康唑
JP2001504121A (ja) * 1996-11-12 2001-03-27 セプラコール,インク. 2r,4s,r,s―および2s,4r,r,s―ヒドロキシイトラコナゾール―およびヒドロキシサパーコナゾール誘導体
CN1102592C (zh) * 1996-11-12 2003-03-05 塞普拉科公司 2r,4s,s,s-和2s,4r,s,s-羟基伊曲康唑
US5684197A (en) * 1996-12-12 1997-11-04 Schering Corporation Process for preparation of hydrazides
CA2262791C (en) * 1997-02-11 2008-10-28 Janssen Pharmaceutica N.V. Amino acid ester containing azole antifungals
US6043245A (en) * 1997-09-25 2000-03-28 Schering Corporation Tetrahydrofuran antifungal phosphate
CN1125066C (zh) * 1997-09-25 2003-10-22 先灵公司 作为相应抗真菌剂前药的四氢呋喃羟基酯
ID29290A (id) * 1997-10-07 2001-08-16 Schering Corp Susunan kristal bentuk-banyak yang dapat membasmi jamur
AU9592998A (en) * 1997-10-07 1999-04-27 Schering Corporation Crystalline antifungal glycine ester polymorph
US6713481B1 (en) * 1997-10-17 2004-03-30 David R. Andrews Crystalline antifungal polymorph
US5883097A (en) * 1998-04-16 1999-03-16 Schering Corporation Soluble azole antifungal salt
EP0957101A1 (en) * 1998-05-14 1999-11-17 Janssen Pharmaceutica N.V. Water soluble azoles as broad-spectrum antifungals
US6147077A (en) * 1999-04-29 2000-11-14 Sepracor Inc. 2R,4S-hydroxyitraconazole isomers
PL351749A1 (en) * 1999-05-04 2003-06-16 Janssen Pharmaceutica Nv Antifungal ethers
US6362172B2 (en) 2000-01-20 2002-03-26 Bristol-Myers Squibb Company Water soluble prodrugs of azole compounds
US6448401B1 (en) 2000-11-20 2002-09-10 Bristol-Myers Squibb Company Process for water soluble azole compounds
HUP0400856A3 (en) * 2001-04-03 2012-09-28 Merck Sharp & Dohme Antifungal composition
US7446107B2 (en) 2002-02-15 2008-11-04 Transform Pharmaceuticals, Inc. Crystalline forms of conazoles and methods of making and using the same
US7078526B2 (en) 2002-05-31 2006-07-18 Transform Pharmaceuticals, Inc. CIS-itraconazole crystalline forms and related processes, pharmaceutical compositions and methods
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
US7790905B2 (en) 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
EP2316469A1 (en) 2002-02-22 2011-05-04 Shire LLC Delivery system and methods for protecting and administering dextroamphetamine
JP4906233B2 (ja) 2002-03-01 2012-03-28 ユニバーシティー オブ サウス フロリダ 少なくとも1種の有効薬剤成分を含有する多構成要素固相
CA2489984A1 (en) 2002-06-21 2003-12-31 Transform Pharmaceuticals, Inc. Pharmaceutical compositions with improved dissolution
US8183290B2 (en) 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
ITMI20032020A1 (it) * 2003-10-17 2005-04-18 Italfarmaco Spa Nuovi agenti antifungini azolici con diminuita interazione con i citocromi metabolici
DE602005012107D1 (de) * 2004-08-13 2009-02-12 Schering Plough Ltd Pharmazeutische formulierungen mit einem antibioti
JO2691B1 (en) * 2005-05-03 2013-03-03 ايساي آر آند دي مانجمنت كو.، ليمتد Monolysine salts for azole compounds
EP2130540A1 (en) * 2008-06-02 2009-12-09 Sandoz AG Pharmaceutical compositions containing a crystalline form of posaconazole
EP2141159A1 (en) 2008-07-03 2010-01-06 Sandoz AG A Crystalline form of posaconazole
WO2011003992A1 (en) 2009-07-09 2011-01-13 Sandoz Ag A crystalline form of posaconazole
WO2011158248A2 (en) * 2010-05-12 2011-12-22 Glenmark Generics Limited Process for preparation of posaconazole and crystalline polymorphic form v of posaconazole
JP2013532131A (ja) * 2010-05-19 2013-08-15 サンド・アクチエンゲゼルシヤフト ポサコナゾール中間体の製造
RU2585683C2 (ru) * 2010-05-19 2016-06-10 Сандоз Аг Очистка позаконазола и промежуточных продуктов для синтеза позаконазола
CN102906087B (zh) * 2010-05-19 2016-03-23 桑多斯股份公司 制备手性三唑酮的方法
RU2588570C2 (ru) * 2010-05-19 2016-07-10 Сандоз Аг Способ получения хиральных гидразидов
PL3391890T3 (pl) 2010-06-29 2021-12-20 Merck Sharp & Dohme Corp. Preparaty dożylnego roztworu pozakonazolu stabilizowane podstawioną beta-cyklodekstryną
US9493428B2 (en) 2011-06-16 2016-11-15 Sandoz Ag Process for the preparation of a chiral compound
EP2789610A1 (en) 2013-04-10 2014-10-15 Sandoz Ag Purification of Posaconazole Intermediates
EP3024828B1 (en) * 2013-07-25 2017-05-17 Sandoz AG Improved process for the preparation of crystalline form iv of posaconazole
ITMI20132114A1 (it) 2013-12-18 2015-06-19 Djada Pharmaceutical Sa Una forma cristallina di posaconazolo
CN105287403A (zh) * 2014-08-02 2016-02-03 陕西合成药业股份有限公司 一种泊沙康唑前体药物的冻干组合物及其制备方法和用途
CN104370894A (zh) * 2014-10-21 2015-02-25 江苏恒盛药业有限公司 无定型泊沙康唑的制备工艺
BR112017008481B1 (pt) 2014-12-05 2022-09-06 Pulmocide Limited Composto antimicótico, uso do referido composto, composição farmacêutica e processo para preparar o mesmo
AU2016263669B2 (en) 2015-05-21 2020-04-30 Pulmocide Limited Antifungal 4-(4-(4-(((3R,5R)-5-((1H-1,2,4-triazol-1-yl)methyl)-5-(2,4- difluorophenyl)tetrahydrofuran-3-yl) methoxy)-3-methylphenyl)piperazin-1-yl)-N- (2-hydroxycyclohexyl) benzamide, or a pharmaceutically acceptable salt thereof
CN106317032A (zh) * 2015-06-15 2017-01-11 重庆圣华曦药业股份有限公司 一种制备高纯度的泊沙康唑的方法
CN106432338A (zh) * 2015-08-08 2017-02-22 陕西合成药业股份有限公司 泊沙康唑衍生物、合成和在长效制剂中的用途
BR112018005934A2 (pt) * 2015-09-23 2018-10-09 Biocon Ltd formas cristalinas de intermediário de posaconazol e processo para a preparação de posaconazol amorfo
CN105606736A (zh) * 2016-01-27 2016-05-25 重庆华邦制药有限公司 分离测定泊沙康唑中间体z1及其有关物质的方法
SI3424911T1 (sl) * 2016-03-04 2021-11-30 Zhejiang Ausun Pharmaceutical Co., Ltd., Posakonazol, sestavek, intermediat, postopek priprave le-tega in uporabe le-tega
CN105949278B (zh) * 2016-03-30 2019-12-06 南京曼杰生物科技有限公司 一种取代的四氢呋喃水溶性衍生物及其应用
WO2017032908A1 (en) 2016-07-08 2017-03-02 Synthon B.V. Pharmaceutical composition comprising amorphous posaconazole
EP3558304A2 (en) 2016-12-23 2019-10-30 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Inhibitors of cytochrome p450 family 7 subfamily b member 1 (cyp7b1) for use in treating diseases
TR201620462A2 (tr) 2016-12-31 2018-07-23 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi POSAKONAZOL İÇEREN FARMASÖTİK BİLEŞİMLER ve ÜRETİM YÖNTEMİ
CN106967054A (zh) * 2017-03-30 2017-07-21 成都绿林科技有限公司 一种泊沙康唑的制备方法
CN106883221A (zh) * 2017-04-17 2017-06-23 兰州大学 一种无定形泊沙康唑及其制备方法
CN108341754A (zh) * 2018-03-12 2018-07-31 扬子江药业集团有限公司 泊沙康唑杂质及其制备方法和用途
CN110938093B (zh) * 2018-09-21 2022-08-19 华创合成制药股份有限公司 一种泊沙康唑磷酸酯单胆碱盐及其制备方法和用途
CN112778369B (zh) * 2019-11-05 2024-01-26 华创合成制药股份有限公司 一种三唑类衍生物及其制备方法和用途
GB201917867D0 (en) 2019-12-06 2020-01-22 Pulmocide Ltd Polymorphs
CN113666915B (zh) * 2021-08-27 2022-08-16 江苏海洋大学 一种泊沙康唑中间体的制备方法
CN114315811B (zh) * 2021-11-19 2024-04-30 江苏恒盛药业有限公司 一种三氮唑类似物化合物及其制备方法和应用
CN120794964A (zh) * 2025-07-03 2025-10-17 广州绿十字制药股份有限公司 泊沙康唑脂肪酸酯、泊沙康唑脂肪酸酯脂肪乳及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4218458A (en) * 1978-06-23 1980-08-19 Janssen Pharmaceutica, N.V. Heterocyclic derivatives of (4-aryloxy-methyl-1,3-dioxolan-2-yl)methyl-1H-imidazoles and 1H-1,2,4-triazoles
CA1292472C (en) * 1985-12-03 1991-11-26 Alfonsus Guilielmus Knaeps Derivatives of ¬¬4-¬4-(4-phenyl-1-piperazinyl)- phenoxymethyl|-1,3-dioxolan-2-yl|methyl|-1h-imidazoles and 1h-1,2,4-triazoles
JPH0717634B2 (ja) * 1987-11-20 1995-03-01 シェリング・コーポレーション トリ‐およびテトラ‐置換‐オキセタンおよびテトラヒドロフランおよびその中間体
US5039676A (en) * 1990-05-11 1991-08-13 Schering Corporation Tri- and tetra-substituted-oxetanes and tetrahydrofurans and intermediates thereof
IL103558A0 (en) * 1991-10-30 1993-03-15 Schering Corp Tri-substituted tetrahydrofuran antifungals

Also Published As

Publication number Publication date
NL300219I1 (nl) 2006-04-03
CZ180596A3 (en) 1997-01-15
HU225062B1 (en) 2006-05-29
CN1064685C (zh) 2001-04-18
AU1512795A (en) 1995-07-10
ATE204875T1 (de) 2001-09-15
ES2159623T3 (es) 2001-10-16
FI118470B (fi) 2007-11-30
TW377349B (en) 1999-12-21
NL300219I2 (nl) 2006-05-01
NO962616D0 (no) 1996-06-20
MY130217A (en) 2007-06-29
DE122006000004I2 (de) 2007-03-29
NO2006002I1 (no) 2006-02-20
NO962616L (no) 1996-08-07
HUT75879A (en) 1997-05-28
FR06C0009I1 (enExample) 2006-05-19
SK283035B6 (sk) 2003-02-04
CA2179396A1 (en) 1995-06-29
WO1995017407A1 (en) 1995-06-29
JPH09500658A (ja) 1997-01-21
IL112081A (en) 2001-08-26
LU91216I2 (en) 2006-03-27
CN1142828A (zh) 1997-02-12
HU9601709D0 (en) 1996-08-28
PL315169A1 (en) 1996-10-14
DE69428125D1 (de) 2001-10-04
PT736030E (pt) 2002-01-30
NO316173B1 (no) 2003-12-22
SK82696A3 (en) 1997-03-05
AU681753B2 (en) 1997-09-04
JP2834889B2 (ja) 1998-12-14
BR1100154B1 (pt) 2013-11-26
NZ278713A (en) 1997-12-19
IL112081A0 (en) 1995-03-15
FI962577L (fi) 1996-06-20
FI962577A0 (fi) 1996-06-20
DE69428125T2 (de) 2002-05-02
DK0736030T3 (da) 2001-10-29
PL181193B1 (pl) 2001-06-29
HK1008820A1 (en) 1999-05-21
CZ294823B6 (cs) 2005-03-16
CA2179396C (en) 2001-04-17
EP0736030A1 (en) 1996-10-09
DE122006000004I1 (de) 2006-04-27
ZA9410142B (en) 1996-05-02
CO4520281A1 (es) 1997-10-15
KR0179990B1 (en) 1999-03-20
EP0736030B1 (en) 2001-08-29
NO2006002I2 (no) 2011-03-07

Similar Documents

Publication Publication Date Title
TW281721B (enExample)
FR06C0009I2 (enExample)
EP0663652A3 (enExample)
IN184543B (enExample)
DK114893D0 (enExample)
EP0644696A3 (enExample)
DK144093D0 (enExample)
EP0725461A3 (enExample)
DK31093D0 (enExample)
DK0611885T3 (enExample)
EP0708807A4 (enExample)
FR2702441B1 (enExample)
DK0645781T3 (enExample)
TW248577B (enExample)
TW282400B (enExample)
EP0714566A4 (enExample)
FR2707037B1 (enExample)
ECSDI930094S (enExample)
IN182003B (enExample)
ECSDI930174S (enExample)
ECSDI930122S (enExample)
IN176923B (enExample)
IN177737B (enExample)
CU22427A3 (enExample)
DK121693D0 (enExample)